For instance, studies have investigated the prevention of diabetic nephropathy progression through the blocking of monocyte recruitment with small molecules, such as a specific CCR2 or dual CCR2/CCR5 antagonist (160, 161). Here, CCR2 is linked to diabetic kidney disease.